The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Neto, José Abraão Carneiro; Bittencourt, Valéria; Oliveira, Cassius de; Andrade, Rosana; Carvalho, Edgar M.

doi:10.1590/0037-8682-0029-2014

Cited by 5 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the toxic effects of anticholinergic drugs may sometimes outweigh their treatment efficacy. Carneiro et al reported the efficacy of botulinum toxin type A for HAM/TSP‐associated OAB refractory to conventional drug in 3 patients. Botulinum toxin type A, a neuromuscular blocking agent, has been used to treat neurogenic OAB following detrusor overactivity in patients with multiple sclerosis and spinal cord injury .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, it has been reported that HAM/TSP patients with neurogenic bladder may also have urinary tract infection and voiding dysfunction . In fact, 1 of the 3 patients in report of Carneiro et al showed an increase in PVR from 32 to 410 mL after botulinum toxin type A intravesical injection therapy . Thus, an effective treatment strategy for lower urinary tract dysfunction in HAM/TSP patients has not yet been established.…”

Section: Discussionmentioning

confidence: 99%

“…However, there are only a few reports on the efficacy of medications for OAB associated with HAM/TSP. Moreover, HAM/TSP patients with LUTS are not fully satisfied with the efficacy of some medications . In some of these patients, the anticholinergic agents prescribed for OAB symptoms caused severe adverse effects, such as constipation and dry mouth, which are autonomic symptoms.…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, although methylprednisolone has often been used in HAM/TSP patients with neurogenic bladder, it has limitations in improving LUTS . In addition to these treatments, some advanced medical treatments, such as botulinum toxin type A, have been tried . However, these studies did not conclusively prove the efficacy and safety of these treatments because of the small number of patients involved.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy

Matsuo

Miyata

Nakamura

et al. 2018

LUTS

View full text Add to dashboard Cite

Objective: Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM/TSP patients with OAB symptoms.Methods: The present study evaluated the efficacy of mirabegron treatment (50 mg, once daily) in nineteen HAM/TSP patients with OAB symptoms by assessing subjective symptoms using the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) before and 12 weeks after administration. Voided volume (VV), maximum flow rate (Q max ), and post-void residual (PVR) urine volume were evaluated as objective symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy

Matsuo

Miyata

Nakamura

et al. 2018

LUTS

View full text Add to dashboard Cite

show abstract

“…Previous reports have indicated that BoNTA intravesical instillation therapy was effective in patients with neurogenic OAB caused by multiple sclerosis or spinal cord injury 15,16 . However, there have been only two reports of the same group on the efficacy of BoNTA in patients with neurogenic OAB due to HAM/TSP refractory to conventional treatment 17,18 . Carneiro et al reported that total OABSS improved from 13.0 to 1.0 in 10 patients (3 probable HAM/TSP and 7 HAM/TSP) 30 days after BoNTA treatment 13 .…”

Section: Discussionmentioning

confidence: 99%

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

et al. 2021

View full text Add to dashboard Cite

Introduction Neurogenic overactive bladder is a main feature of human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. We successfully performed intravesical onabotulinumtoxinA therapy for refractory neurogenic overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. Case presentation We retrospectively reviewed four neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis who underwent bladder wall injections of onabotulinumtoxinA from April to October 2020. All patients were female. Their median age was 66 (range, 63–71) years. They were previously treated with β3‐adrenergic receptor agonists or anticholinergic drugs alone or in combination for ≥12 weeks. However, insufficient results were obtained. After 4 weeks of intravesical onabotulinumtoxinA therapy, overactive bladder symptoms improved and maximum cystometric capacity increased in all cases. Conclusion Intravesical onabotulinumtoxinA therapy may be useful for treating refractory overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis.

show abstract

Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A

Paradella¹,

Musegante²,

Brites³

2016

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

Intravesical botulinum toxin A (BoNTA) injection has been widely used for the treatment of detrusor overactivity in patients with neurogenic bladder due to spinal cord injury who do not respond to conventional treatment. There is no consensus about antibiotic prophylaxis for this procedure. We conducted a retrospective analysis of medical records of adult patients with spinal cord injury who underwent detrusor BoNTA injection between January of 2007 and December of 2013 in a rehabilitation hospital. Occurrence of symptomatic urinary tract infection (UTI) was assessed in 3 groups in accordance with their use of antibiotics (prophylactic dosage, 3 days, more than 3 days) for the treatment of asymptomatic bacteriuria. All patients were performing self or assisted clean intermittent bladder catheterization and underwent a rigid cystoscopy, under general or regional anesthesia with sedation, and the drug used was Botox. A total of 616 procedures were performed during the study period. There were 11 identified cases of UTI (1.8%) with a trend to a higher rate in the group that used antibiotics for longer time. This report shows that a single dose of antibiotics before the detrusor BoNTA injection is enough to prevent UTI. Randomized clinical trial should be conducted for definitive conclusions.

show abstract

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Cited by 5 publications

References 12 publications

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A

Contact Info

Product

Resources

About